Search

Your search keyword '"Manetti, N"' showing total 3 results
Start Over Author "Manetti, N" Topic 030211 gastroenterology & hepatology
3 results on '"Manetti, N"'

1. Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study

Author

Federica Furfaro, Vito Annese, Alessandro Armuzzi, Walter Fries, Daniela Pugliese, Gaetano Inserra, Maria Cappello, I. Frankovic, Antonino Carlo Privitera, Francesca Calella, Natalia Manetti, Francesco Manguso, Silvio Danese, Flavio Caprioli, Fabrizio Bossa, Matilde Rea, Angela Alibrandi, Laura Cantoro, Giuseppe Scalisi, Giovanni Casella, Stefania Orlando, Sandro Ardizzone, Gionata Fiorino, Anna Viola, Giammarco Mocci, Mariabeatrice Principi, R. Bringiotti, Anna Kohn, Fabiana Castiglione, R. Monterubbianesi, Renata D'Incà, Annalisa Aratari, L. Samperi, Claudio Papi, Simone Saibeni, Viola, A, Monterubbianesi, R, Scalisi, G, Furfaro, F, Rea, M, Saibeni, S, Aratari, A, Bringiotti, R, Casella, G, Cantoro, L, Frankovic, I, Calella, F, Pugliese, D, Orlando, S, Samperi, L, Cappello, M, Mocci, G, Manetti, N, Annese, V, Privitera, Ac, Inserra, G, Caprioli, F, D'Inca, R, Principi, M, Papi, C, Castiglione, F, Danese, S, Ardizzone, S, Bossa, F, Kohn, A, Manguso, F, Alibrandi, A, Fiorino, G, Armuzzi, A, Fries, W, Viola, A., Monterubbianesi, R., Scalisi, G., Furfaro, F., Rea, M., Saibeni, S., Aratari, A., Bringiotti, R., Casella, G., Cantoro, L., Frankovic, I., Calella, F., Pugliese, D., Orlando, S., Samperi, L., Cappello, M., Mocci, G., Manetti, N., Annese, V., Privitera, A. C., Inserra, G., Caprioli, F., D'Inca, R., Principi, M., Papi, C., Castiglione, F., Danese, S., Ardizzone, S., Bossa, F., Kohn, A., Manguso, F., Alibrandi, A., Fiorino, G., Armuzzi, A., and Fries, W.

Subjects
Male, Disease, Constriction, Pathologic, tumours, Inflammatory bowel disease, Late Onset Disorders, Cohort Studies, surgery, 0302 clinical medicine, Crohn Disease, Medicine, Young adult, Digestive System Surgical Procedures, Crohn's disease, Gastroenterology, Ileitis, Middle Aged, Colitis, Italy, 030220 oncology & carcinogenesis, outcome, 030211 gastroenterology & hepatology, Female, Colorectal Neoplasms, Cohort study, steroids, Adult, medicine.medical_specialty, Adolescent, comorbidities, elderly, 03 medical and health sciences, Young Adult, Internal medicine, Intestinal Fistula, Humans, Immunologic Factors, Glucocorticoids, Aged, Retrospective Studies, Polypharmacy, Hepatology, business.industry, thiopurines, Retrospective cohort study, medicine.disease, Tumor Necrosis Factor Inhibitors, business
Abstract

BACKGROUND Disease phenotype and outcome of late-onset Crohn's disease are still poorly defined. METHODS In this Italian nationwide multicentre retrospective study, patients diagnosed ≥65 years (late-onset) were compared with young adult-onset with 16-39 years and adult-onset Crohn's disease 40-64 years. Data were collected for 3 years following diagnosis. RESULTS A total of 631 patients (late-onset 153, adult-onset 161, young adult-onset 317) were included. Colonic disease was more frequent in late-onset (P < 0005), stenosing behaviour was more frequent than in adult-onset (P < 0003), but fistulising disease was uncommon. Surgery rates were not different between the three age groups. Systemic steroids were prescribed more frequently in young adult-onset in the first year, but low bioavailability steroids were used more frequently in late-onset in the first 2 years after diagnosis (P < 0.036, P < 0.041, respectively). The use of immunomodulators and anti-TNF's even in patients with more complicated disease, that is, B2 or B3 behaviour (Montreal classification), remained significantly inferior (P < 0.0001) in late-onset compared to young adult-onset. Age at diagnosis, Charlson comorbidity index, and steroid used in the first year were negatively associated with the use of immunomodulators and biologics. Comorbidities, related medications and hospitalizations were more frequent in late-onset. Polypharmacy was present in 56% of elderly Crohn's disease patients. CONCLUSION Thirty-two percent of late-onset Crohn's disease presented with complicated disease behaviour. Despite a comparable use of steroids and surgery, immunomodulators and biologics were used in a small number of patients.

Published
2019

2. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy

Author

A. Armuzzi, Silvio Danese, Maurizio Vecchi, Fabiana Castiglione, Gianmichele Meucci, Gionata Fiorino, M. Di Girolamo, Natalia Manetti, Sandro Ardizzone, Simone Saibeni, A. Ronchetti, Sara Renna, Giovanni Maconi, Agostino Colli, Giulia Rizzuto, Anna Kohn, Paolo Lionetti, Silvia Ghione, Angela Variola, Agostino Ventra, O. Nardone, Stefano Milani, Silvia Mazzuoli, Maria M. Terpin, Renata D'Incà, V. F. Annese, A. Di Sabatino, A. Orlando, Francesco Perri, Andrea Cassinotti, R. Salerno, Arnaldo Amato, Daniela Pugliese, Lorenzo Bertani, A. Geccherle, S. Saettone, Francesco William Guglielmi, Angelo Andriulli, Francesca Rogai, Fabrizio Bossa, Claudio Camillo Cortelezzi, L. Caserta, E. Troncone, Livia Biancone, Francesco Costa, R. Tari, M. Bosani, Alessandro Massari, Arianna Massella, Maria Cappello, B. Scrivo, Walter Fries, Maria Laura Annunziata, Mariabeatrice Principi, Cristina Bezzio, Laura Cantoro, M.C. Parodi, Gianni Imperiali, Carlo Petruzzellis, Greta Lorenzon, G. Martino, Luisa Guidi, A. Bertani, Armuzzi, Alessandro, Fiorino, Gionata, Variola, Angela, Manetti, Natalia, Fries, Walter, Orlando, Ambrogio, Maconi, Giovanni, Bossa, Fabrizio, Cappello, Maria, Biancone, Livia, Cantoro, Laura, Costa, Francesco, D'Incà, Renata, Lionetti, Paolo, Principi, Mariabeatrice, Castiglione, Fabiana, Annunziata, Maria L, Di Sabatino, Antonio, Di Girolamo, Maria, Terpin, Maria M, Cortelezzi, Claudio C, Saibeni, Simone, Amato, Arnaldo, Ardizzone, Sandro, Guidi, Luisa, Danese, Silvio, Massella, Arianna, Ventra, Agostino, Rizzuto, Giulia, Massari, Alessandro, Perri, Francesco, Annese, Vito, Guidi, L, Fiorino, G, Variola, A, Manetti, N, Fries, W, Rizzuto, G, Bossa, F, Cappello, M, Biancone, L, D'Inca, R, Cantoro, L, Castiglione, F, Principi, M, Annunziata, Ml, Di Girolamo, M, Terpin, Mm, Cortelezzi, Cc, Costa, F, Amato, A, Di Sabatino, A, Saibeni, S, Meucci, G, Petruzzellis, C, Tari, R, Gugliemi, Fw, Armuzzi, A, Danese, S, Geccherle, A, Rogai, F, Ventra, A, Orlando, A, Andriulli, A, Scrivo, B, Troncone, E, Caccaro, R, Kohn, A, Nardone, O, and Annese, V

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, Adolescent, Settore MED/12 - GASTROENTEROLOGIA, Biosimilar, Crohn's disease, CT-P13, Inflammatory bowel disease, Inflectra, Infliximab, Remsima, Ulcerative colitis, Antibodies, Monoclonal, Female, Follow-Up Studies, Gastrointestinal Agents, Humans, Inflammatory Bowel Diseases, Italy, Prognosis, Prospective Studies, Young Adult, Antibodies, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Monoclonal, medicine, Immunology and Allergy, Prospective cohort study, business.industry, ulcerative colitis, inflammatory bowel disease, biosimilar, Settore MED/09 - MEDICINA INTERNA, Gastroenterology, medicine.disease, 030104 developmental biology, Cohort, 030211 gastroenterology & hepatology, Calprotectin, business, Cohort study, medicine.drug
Abstract

BACKGROUND We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. METHODS A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. RESULTS Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naive to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One hundred fifty-four SAEs were reported (19%), leading to cessation of the biosimilar in 103 subjects (12.7%). Infusion reactions were 71, leading to cessation of the biosimilar in 53 subjects (6.5%), being significantly more frequent in patients pre-exposed to anti-TNFα (P = 0.017). The efficacy of therapy was calculated in 754 IBD patients, with a mean follow-up of 329 ± 202 days. Forty-eight patients had a primary failure (6.4%), and 188 (25.6%) lost response during follow-up. Six hundred twenty-eight (364 CD) and 360 IBD patients (222 CD) completed the follow-up at 6 and 12 months, respectively. At 12 months, patients without loss of response were 71%, 64%. and 82% in groups A, B, and C, respectively (log rank P = 0.01). Clinical/endoscopic scores and inflammatory biomarkers dropped significantly in CD and UC patients (P = 0.01 and P < 0.0001) compared with baseline. CONCLUSIONS In this large prospective cohort, no further signals of difference in safety and effectiveness of CT-P13 in IBD has been observed.

Published
2018

3. Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD 'AGED study'

Author

Gionata Fiorino, Anna Viola, Maria Cappello, Vito Annese, Anna Kohn, R. Monterubbianesi, Renata D'Incà, Daniela Pugliese, Natalia Manetti, Fabrizio Bossa, Claudio Papi, L. Samperi, Gaetano Inserra, Francesca Calella, Mariabeatrice Principi, Giammarco Mocci, Giovanni Casella, Antonella Contaldo, Alessandro Armuzzi, Fabiana Castiglione, Antonino Carlo Privitera, Andrea Magarotto, Francesco Manguso, Annalisa Aratari, Stefanos Bonovas, Angela Alibrandi, Federica Furfaro, Flavio Caprioli, Matilde Rea, Laura Cantoro, Silvio Danese, Giuseppe Scalisi, Sandro Ardizzone, Simone Saibeni, Walter Fries, I. Frankovic, Fries, Walter, Viola, Anna, Manetti, Natalia, Frankovic, Iri, Pugliese, Daniela, Monterubbianesi, Rita, Scalisi, Giuseppe, Aratari, Annalisa, Cantoro, Laura, Cappello, Maria, Samperi, Leonardo, Saibeni, Simone, Casella, Giovanni, Mocci, Giammarco, Rea, Matilde, Furfaro, Federica, Contaldo, Antonella, Magarotto, Andrea, Calella, Francesca, Manguso, Francesco, Inserra, Gaetano, Privitera, Antonino C, Principi, Mariabeatrice, Castiglione, Fabiana, Caprioli, Flavio, Ardizzone, Sandro, Danese, Silvio, Papi, Claudio, Bossa, Fabrizio, Kohn, Anna, Armuzzi, Alessandro, D'Incà, Renata, Annese, Vito, Alibrandi, Angela, Bonovas, Stefano, Fiorino, Gionata, Fries, W, Viola, A, Manetti, N, Frankovic, I, Pugliese, D, Monterubbianesi, R, Scalisi, G, Aratari, A, Cantoro, L, Cappello, M, Samperi, L, Saibeni, S, Casella, G, Mocci, G, Rea, M, Furfaro, F, Contaldo, A, Magarotto, A, Calella, F, Manguso, F, Inserra, G, Privitera, Ac, Principi, M, Castiglionen, F, Caprioli, F, Ardizzone, S, Danese, S, Papi, C, Bossa, F, Kohn, A, Armuzzi, A, D'Inca, R, Annese, V, Alibrandi, A, Bonovas, S, and Fiorino, G

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Disease, Gastroenterology, Severity of Illness Index, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Risk Factors, Internal medicine, Severity of illness, medicine, Humans, Immunologic Factors, Young adult, Age of Onset, Steroid, Thiopurines, Colectomy, Outcome, Tumors, Aged, Retrospective Studies, Steroids, Surgery, Hepatology, Thiopurine, business.industry, Retrospective cohort study, Middle Aged, medicine.disease, Ulcerative colitis, Natural history, Logistic Models, Italy, Disease Presentation, 030220 oncology & carcinogenesis, Disease Progression, 030211 gastroenterology & hepatology, Colitis, Ulcerative, Female, Age of onset, business
Abstract

Background: Late-onset UC represents an important issue for the near future, but its outcomes and relative therapeutic strategies are yet poorly studied. Aim: To better define the natural history of late-onset ulcerative colitis. Methods: In a multicenter retrospective study, we investigated the disease presentation and course in the first 3 years in 1091 UC patients divided into 3 age-groups: diagnosis >65 years, 40-64 years, and

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results